101 related articles for article (PubMed ID: 26612479)
1. Response of patients with indolent systemic mastocytosis to tamoxifen citrate.
Butterfield JH; Chen D
Leuk Res; 2016 Jan; 40():10-6. PubMed ID: 26612479
[TBL] [Abstract][Full Text] [Related]
2. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
[TBL] [Abstract][Full Text] [Related]
3. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers predictive for bone marrow involvement in systemic mastocytosis.
Donker ML; van Doormaal JJ; van Doormaal FF; Kluin PM; van der Veer E; de Monchy JG; Kema IP; Kluin-Nelemans HC
Haematologica; 2008 Jan; 93(1):120-3. PubMed ID: 18166795
[TBL] [Abstract][Full Text] [Related]
5. Survey of aspirin administration in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2009 Apr; 88(3-4):122-4. PubMed ID: 19429499
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?
Butterfield JH; Li CY
Am J Clin Pathol; 2004 Feb; 121(2):264-7. PubMed ID: 14983941
[TBL] [Abstract][Full Text] [Related]
7. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
8. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
9. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
10. The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis.
Raithel M; Zopf Y; Kimpel S; Naegel A; Molderings GJ; Buchwald F; Schultis HW; Kressel J; Hahn EG; Konturek P
J Physiol Pharmacol; 2011 Aug; 62(4):469-72. PubMed ID: 22100848
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.
Butterfield JH; Tefferi A; Kozuh GF
Leuk Res; 2005 Feb; 29(2):131-4. PubMed ID: 15607359
[TBL] [Abstract][Full Text] [Related]
12. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Whelan TJ; Goss PE; Ingle JN; Pater JL; Tu D; Pritchard K; Liu S; Shepherd LE; Palmer M; Robert NJ; Martino S; Muss HB
J Clin Oncol; 2005 Oct; 23(28):6931-40. PubMed ID: 16157934
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of indolent mastocytosis in adults.
Kors JW; Van Doormaal JJ; Breukelman H; Van Voorst Vader PC; De Monchy JG
J Intern Med; 1996 Feb; 239(2):157-64. PubMed ID: 8568484
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and adjuvant tamoxifen treatment in breast cancer patients.
Boehm DU; Lebrecht A; Eckhardt T; Albrich S; Schmidt M; Siggelkow W; Kandelhardt E; Koelbl H
Eur J Cancer Care (Engl); 2009 Sep; 18(5):500-6. PubMed ID: 19490009
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes.
Graves L; Stechschulte DJ; Morris DC; Lukert BP
J Bone Miner Res; 1990 Nov; 5(11):1113-9. PubMed ID: 2270775
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Ohsumi S; Shimozuma K; Ohashi Y; Shinji M; Hozumi Y; Mukai H; Takatsuka Y; Aihara T
Breast Cancer Res Treat; 2011 May; 127(1):143-52. PubMed ID: 21347648
[TBL] [Abstract][Full Text] [Related]
17. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects.
Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN
J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis.
van Toorenenbergen AW; Oranje AP
Clin Chim Acta; 2005 Sep; 359(1-2):72-7. PubMed ID: 15913591
[TBL] [Abstract][Full Text] [Related]
19. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.
Florian S; Krauth MT; Simonitsch-Klupp I; Sperr WR; Fritsche-Polanz R; Sonneck K; Födinger M; Agis H; Böhm A; Wimazal F; Horny HP; Valent P
Int Arch Allergy Immunol; 2005 Mar; 136(3):273-80. PubMed ID: 15722637
[TBL] [Abstract][Full Text] [Related]
20. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
